Immune checkpoint inhibitors for treatment of biliary malignant tumors

Guoming SHI; Yanzhi PEI; Pinxiang LU; Jun CAO; Jian ZHOU; Jia FAN

doi:10.3969/j.issn.1001-5256.2022.05.005

Volume 38 Issue 5

May 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(5): 998-1001

PDF( 1877 KB)

Immune checkpoint inhibitors for treatment of biliary malignant tumors

DOI: 10.3969/j.issn.1001-5256.2022.05.005

1.
Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai 200032, China
2.
Department of General Surgery, Xuhui District Central Hospital, Shanghai 200032, China
3.
Department of Interventional Oncology, Dahua Hospital, Xuhui District, Shanghai 200032, China

Research funding:

The Clinical Research Plan of SHDC (SHDC2020CR1003A);

Key Projects of Major Diseases in Xuhui District (XHLHG202103)

More Information

Corresponding author: SHI Guoming, shi.guoming@zs-hospital.sh.cn(ORCID: 0000-0003-3817-9117)
Received Date: 2022-02-22
Accepted Date: 2022-03-22
Published Date: 2022-05-20

Abstract

Abstract

Biliary malignant tumors have an insidious onset and rapid development, and most patients have lost the opportunity for radical surgery at initial diagnosis and often have poor prognosis. Gemcitabine-based chemotherapy is the first-line treatment for biliary malignant tumors, but with a limited clinical effect. The improvement in next-generation sequencing technology provides the possibility for the precise treatment of biliary malignant tumors, but the application and development of the precise treatment of biliary malignant tumors are limited by the low positive rate of targets and the poor accessibility of therapeutic drugs. The advent of the era of immunotherapy represented by the immune checkpoint inhibitor PD1/PD-L1 monoclonal antibody brings a promising future for the treatment of malignant tumors, including biliary malignant tumors. Combined chemotherapy and/or targeted therapy based on immune checkpoint inhibitors has shown a good effect in the treatment of biliary malignant tumors, which is the direction of the treatment of advanced biliary malignant tumors in the future.
- Biliary Tract Neoplasms,
- Drug Therapy, Combination,
- Molecular Targeted Therapy,
- Immunosuppressive Agents

FullText(HTML)

References(22)

References

[1]	SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]	LU JC, ZENG HY, SUN QM, et al. Distinct PD-L1/PD1 profiles and clinical implications in intrahepatic cholangiocarcinoma patients with different risk factors[J]. Theranostics, 2019, 9(16): 4678-4687. DOI: 10.7150/thno.36276.
[3]	VALLE J, WASAN H, PALMER DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281. DOI: 10.1056/NEJMoa0908721.
[4]	ABOU-ALFA GK, SAHAI V, HOLLEBECQUE A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2020, 21(5): 671-684. DOI: 10.1016/S1470-2045(20)30109-1.
[5]	FENG YH. Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations[R]. 2022 ASCO GI430#
[6]	ABOU-ALFA GK, MACARULLA T, JAVLE MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(6): 796-807. DOI: 10.1016/S1470-2045(20)30157-1.
[7]	GUO XJ, LU JC, ZENG HY, et al. CTLA-4 synergizes with PD1/PD-L1 in the inhibitory tumor microenvironment of intrahepatic cholangiocarcinoma[J]. Front Immunol, 2021, 12: 705378. DOI: 10.3389/fimmu.2021.705378.
[8]	HASLAM A, PRASAD V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs[J]. JAMA Netw Open, 2019, 2(5): e192535. DOI: 10.1001/jamanetworkopen.2019.2535.
[9]	HOOS A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations[J]. Nat Rev Drug Discov, 2016, 15(4): 235-247. DOI: 10.1038/nrd.2015.35.
[10]	MOTZER RJ, TANNIR NM, MCDERMOTT DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma[J]. N Engl J Med, 2018, 378(14): 1277-1290. DOI: 10.1056/NEJMoa1712126.
[11]	OVERMAN MJ, MCDERMOTT R, LEACH JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study[J]. Lancet Oncol, 2017, 18(9): 1182-1191. DOI: 10.1016/S1470-2045(17)30422-9.
[12]	OVERMAN MJ, LONARDI S, WONG K, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol, 2018, 36(8): 773-779. DOI: 10.1200/JCO.2017.76.9901.
[13]	SCHMID P, ADAMS S, RUGO HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J]. N Engl J Med, 2018, 379(22): 2108-2121. DOI: 10.1056/NEJMoa1809615.
[14]	GANDHI L, RODRÍGUEZ-ABREU D, GADGEEL S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22): 2078-2092. DOI: 10.1056/NEJMoa1801005.
[15]	NAKAMURA H, ARAI Y, TOTOKI Y, et al. Genomic spectra of biliary tract cancer[J]. Nat Genet, 2015, 47(9): 1003-1010. DOI: 10.1038/ng.3375.
[16]	ZHOU G, SPRENGERS D, MANCHAM S, et al. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules[J]. J Hepatol, 2019, 71(4): 753-762. DOI: 10.1016/j.jhep.2019.05.026.
[17]	SILVA VW, ASKAN G, DANIEL TD, et al. Biliary carcinomas: Pathology and the role of DNA mismatch repair deficiency[J]. Chin Clin Oncol, 2016, 5(5): 62. DOI: 10.21037/cco.2016.10.04.
[18]	MARABELLE A, LE DT, ASCIERTO PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2020, 38(1): 1-10. DOI: 10.1200/JCO.19.02105.
[19]	PIHA-PAUL SA, OH DY, UENO M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies[J]. Int J Cancer, 2020, 147(8): 2190-2198. DOI: 10.1002/ijc.33013.
[20]	KIM RD, CHUNG V, ALESE OB, et al. A Phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J]. JAMA Oncol, 2020, 6(6): 888-894. DOI: 10.1001/jamaoncol.2020.0930.
[21]	JIAN Z, FAN J, SHI GM, et al. Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial[J]. J Clin Oncol, 2021, 39(15_suppl): 4099. https://www.researchgate.net/publication/352072246_Lenvatinib_plus_toripalimab_as_first-line_treatment_for_advanced_intrahepatic_cholangiocarcinoma_A_single-arm_phase_2_trial
[22]	KEMP A. Imfinzi plus chemotherapy significant improved overall survival in 1st-line advanced biliary tract cancer in TOPAZ-1 phase Ⅲ trial at interim analysis[EB/OL]. (2021-10-25). News release. AstraZeneca. https://bit.ly/3vMk79.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (717) PDF downloads(139)

Immune checkpoint inhibitors for treatment of biliary malignant tumors

DOI: 10.3969/j.issn.1001-5256.2022.05.005

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Immune checkpoint inhibitors for treatment of biliary malignant tumors

DOI: 10.3969/j.issn.1001-5256.2022.05.005

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content